NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»20/01/2010 [Industry news]
CEO of NeoStem, Inc. Says China Will Play a Key Role in Company Future

\"We think therapy is what is going to drive our business model; our company has grown over the last two and a half years from a single line to being a real therapeutics company,\" says Smith.

 
BioMedReports.Com, the news portal which covers Wall Street\'s biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has an exclusive interview with Robin L. Smith M.D., Chairman of the Board, Chief Executive Officer, of NeoStem . NeoStem is engaged in the business of developing stem cell therapies, pursuing anti-ageing initiatives and is operating a network of adult stem cell collection centres that are focused on enabling people to donate and store stem cells for their personal use in times of future medical need. \"We think therapy is what is going to drive our business model; our company has grown over the last two and a half years from a single line to being a real therapeutics company,\" says Smith. \"Our recently announced expansion into China is just that. We purchased a pharmaceutical company doing $60 million in revenue and we own 51% of that.\" \"It pays off right away because we are going from $80K in revenue to $60 million. So it pays off in that regard, and it\'s very profitable. To continue to enhance that piece of the business as China is going through their health care reform is important. We are very well poised to accept some of those revenues and grow in that area. But on top of that we can bring new innovative drugs and technologies, with our expertise, right into China. Right into that pipeline. So we think that is a tremendous opportunity today.\"

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.